Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Naltrexone 50 Mg Film Tablet:
Orpha Swiss GmbH Switzerland flag Switzerland
Abstract ID:
Opioid receptor blocker which reduces desire for opioids and alcohol, use in psychiatry, neurology and addition medicine....
Contact
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
Competitive Blocker of mu, kappa and delta opioid receptors.

Naltrexone is a Mu-, Kappa and Delta-Receptor Antagonist. It has a stronger affinity to the opioid receptors than any opioid. It is indicated as adjunctive therapy in the maintenance of formerly opioid dependent patients who have ceased the use of opioids such as e.g. Heroin or Morphine. Naltrexone is also indicated in the treatment of alcohol dependence, as a component of a comprehensive psychotherapeutic or psychological alcoholism counselling program to support abstinence and reduce the risk of relapse. Target groups are Drug Treatment Centres, psychiatrists and physicians treating former opioid- or alcohol addicts.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Country-specific or regional distribution contract

FEATURED
Last Updated Oct 2014
Technology Type THERAPEUTIC
Phase of Development REGISTERED / FINISHED PRODUCT
CORPORATION
Company Logo